Allogenic antibody-mediated identification of head and neck cancer antigens

Recently, we described a new target-identification technology, autoantibody-mediated identification of antigens (AMIDA). AMIDA takes advantage of autologous serum autoantibodies to identify disease-associated antigens. Here, we evaluated the allogenic variant of AMIDA (allo-AMIDA), using permanent c...

Full description

Saved in:
Bibliographic Details
Published in:Biochemical and biophysical research communications 2004-10, Vol.323 (1), p.156-162
Main Authors: Rauch, Jens, Ahlemann, Martin, Schaffrik, Martina, Mack, Brigitte, Ertongur, Suna, Andratschke, Michaela, Zeidler, Reinhard, Lang, Stephan, Gires, Olivier
Format: Article
Language:English
Subjects:
Adaptor Proteins, Signal Transducing - biosynthesis
AMIDA
Antigens, Neoplasm - chemistry
Autoantibodies - chemistry
Bio-Plex
Carrier Proteins - biosynthesis
Cell Line, Tumor
e-FABP
Electrophoresis, Gel, Two-Dimensional
Epithelium - metabolism
Fatty Acid-Binding Proteins
Grb2
GRB2 Adaptor Protein
Head and Neck Neoplasms - immunology
Head and Neck Neoplasms - metabolism
Heterogeneous-Nuclear Ribonucleoproteins - biosynthesis
hnRNP H
Humans
Immunohistochemistry
Immunologic Techniques
Immunologic Tests
Immunoprecipitation
Neoplasm Metastasis
Recombinant Proteins - chemistry
Serum antibodies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recently, we described a new target-identification technology, autoantibody-mediated identification of antigens (AMIDA). AMIDA takes advantage of autologous serum autoantibodies to identify disease-associated antigens. Here, we evaluated the allogenic variant of AMIDA (allo-AMIDA), using permanent cancer cell lines as an antigen-pool rather than primary biopsy samples. Twelve different proteins were retrieved exclusively with antibodies from cancer patients, but not from healthy donors. The expression of three of these antigens, e-FABP, hnRNP H, and Grb2, was evaluated in more detail. All three proteins were strongly overexpressed in primary carcinomas and metastases thereof, as compared to healthy epithelium. Additionally, serum reactivity against e-FABP was detected in 20% of cancer patients but only 2% of healthy volunteers. In summary, we demonstrate that permanent cancer cell lines represent a reliable source for tumour-associated antigens. Moreover, we show that allo-AMIDA is suitable for the identification of tumour-specific antigens overcoming the limitations of autologous screening techniques.
ISSN:0006-291X
1090-2104
DOI:10.1016/j.bbrc.2004.08.071